| Bioactivity | Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1]. |
| Invitro | Zalifrelimab（AGEN1884；0.1、1、10 或 100 μg/mL）有效增强抗原特异性 T 细胞反应性，可与其他免疫调节抗体联合使用。Zalifrelimab 与 PD-1 阻断剂有效结合，可在外周引起 T 细胞增殖反应[2]。 |
| In Vivo | Zalifrelimab（AGEN1884；10 mg/kg；静脉注射；第 1 天和第 29 天）在非人灵长类动物中具有良好的耐受性，可增强疫苗介导的抗原特异性免疫[2]。 Animal Model: |
| Name | Zalifrelimab |
| CAS | 2148321-69-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. David M O'Malley, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771. [2]. Randi B Gombos, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018 Apr 4;13(4):e0191926. |